These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641 [No Abstract] [Full Text] [Related]
3. Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry. Xu C; Yin Y Methods Mol Biol; 2020; 2108():159-165. PubMed ID: 31939179 [TBL] [Abstract][Full Text] [Related]
4. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models. Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023 [TBL] [Abstract][Full Text] [Related]
5. High-Throughput Flow Cytometric Method for the Simultaneous Measurement of CAR-T Cell Characterization and Cytotoxicity against Solid Tumor Cell Lines. Martinez EM; Klebanoff SD; Secrest S; Romain G; Haile ST; Emtage PCR; Gilbert AE SLAS Discov; 2018 Aug; 23(7):603-612. PubMed ID: 29634393 [TBL] [Abstract][Full Text] [Related]
7. Generation of CAR-T Cells for Cancer Immunotherapy. Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215 [TBL] [Abstract][Full Text] [Related]
8. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536 [TBL] [Abstract][Full Text] [Related]
9. Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors. Rodriguez-Garcia A; Watanabe K; Guedan S Methods Mol Biol; 2020; 2086():251-271. PubMed ID: 31707682 [TBL] [Abstract][Full Text] [Related]
10. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399 [TBL] [Abstract][Full Text] [Related]
11. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses. Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066 [TBL] [Abstract][Full Text] [Related]
12. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199 [TBL] [Abstract][Full Text] [Related]
13. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. Wang L; Gong W; Wang S; Neuber B; Sellner L; Schubert ML; Hückelhoven-Krauss A; Kunz A; Gern U; Michels B; Hinkelbein M; Mechler S; Richter P; Müller-Tidow C; Schmitt M; Schmitt A Cytotherapy; 2019 May; 21(5):566-578. PubMed ID: 30910382 [TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer. Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795 [TBL] [Abstract][Full Text] [Related]
16. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702 [TBL] [Abstract][Full Text] [Related]
17. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer. Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314 [TBL] [Abstract][Full Text] [Related]
18. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Kosti P; Maher J; Arnold JN Front Immunol; 2018; 9():1104. PubMed ID: 29872437 [TBL] [Abstract][Full Text] [Related]
19. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735 [TBL] [Abstract][Full Text] [Related]